The latest News broadcast from Andrew Schorr at the ASH conference may have just hit your
in box? You can view it here:
Dr. John Pagel, from the Seattle Cancer Care Alliance, discusses the advances that
signal a potentially changing treatment landscape in CLL Pagel explains some of the new drug
therapies, including insights from ASH 2012, that may mean a move away from chemotherapy
for some patients.
Ibrutinib, GS 1101 and ABT-199 are changing the CLL treatment landscape, plus antibody
therapies such as GA 101 and novel therapies such as TRUO16 and the exciting T cell mediated therapies in research CART etc. All of these are moving away from toxicity treatments for the future.
Interesting times, The New Clinical Trials will be discussed with us at Cardiff in January by Professor Chris Fegan a clinical trials expert.
UK Trials portfolio ncrndev.org.uk/downloads/Tr...